Clincosm LogoSign in Get a demo

Patient Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT05761093
Collaborator
(none)
306
Enrollment
1
Location
18.8
Anticipated Duration (Months)
16.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The objective of this study is to examine the preference weightings in term of risk/ benefit attributes of treatment in prostate cancer patients from different stages of disease..

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    306 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Prospective
    Official Title:
    A Study to Evaluate Patient Benefit/ Risk Preferences for Treatment of Metastatic Prostate Cancer (mPC) in Hong Kong: a Discrete Choice Experiment
    Actual Study Start Date :
    Sep 7, 2022
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Mar 31, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Patient preferences for treatment attributes in prostate cancer from different stages of disease [15 minutes (Once through survey)]

      Derived from discrete choice experiment

    Secondary Outcome Measures

    1. To examine the effect of socio-economic status on preference weighing [15 minutes (Once through survey)]

      Derived from discrete choice experiment

    2. To examine the status of comorbidities on preference weighing [15 minutes (Once through survey)]

      Derived from discrete choice experiment

    3. To examine their willingness of trading off survival with improving QOL [15 minutes (Once through survey]

      Derived from discrete choice experiment

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • aged 18 years or older,

    • diagnosis of metastatic prostate cancer within 5 years,

    • able to read and write,

    • accepting and signing the informed consent

    Exclusion Criteria:

    • if patients are unable to complete the survey by themselves due to physical or psychological reasons,

    • deemed ineligible by treating physicians if patients are unable to complete the survey by themselves due to physical or psychological reasons,

    • deemed ineligible by treating physicians

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Prince of Wales Hospital Sha Tin Hong Kong

    Sponsors and Collaborators

    • Chinese University of Hong Kong

    Investigators

    • Principal Investigator: Chi Fai NG, MD, Chinese University of Hong Kong

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Chi Fai NG, Professor, Chinese University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT05761093
    Other Study ID Numbers:
    • CRE-2022.
    First Posted:
    Mar 9, 2023
    Last Update Posted:
    Mar 16, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Prostatic Neoplasms

    Study Results

    No Results Posted as of Mar 16, 2023